Literature DB >> 34162723

Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues.

Ann M Carias1, Jeffrey R Schneider2, Patrick Madden1, Ramon Lorenzo-Redondo3, Mariluz Araínga4, Amarendra Pegu5, Gianguido C Cianci1, Danijela Maric1, Francois Villinger4, John R Mascola5, Ronald S Veazey6, Thomas J Hope7.   

Abstract

i.v. injected Abs have demonstrated protection against simian HIV infection in rhesus macaques, paving the way for the Antibody Mediated Prevention trial in which at-risk individuals for HIV received an i.v. infusion of the HIV broadly neutralizing Ab VRC01. However, the time needed for these Abs to fully distribute and elicit protection at mucosal sites is still unknown. In this study, we interrogate how long it takes for Abs to achieve peak anatomical levels at the vaginal surface following i.v. injection. Fluorescently labeled VRC01 and/or Gamunex-C were i.v. injected into 24 female rhesus macaques (Macaca mulatta) with vaginal tissues and plasma acquired up to 2 wk postinjection. We found that Ab delivery to the vaginal mucosa occurs in two phases. The first phase involves delivery to the submucosa, occurring within 24 h and persisting beyond 1 wk. The second phase is the delivery through the stratified squamous epithelium, needing ∼1 wk to saturate the stratum corneum. This study has important implications for the efficacy of immunoprophylaxis targeting pathogens at the mucosa.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34162723      PMCID: PMC8516693          DOI: 10.4049/jimmunol.2100253

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  24 in total

Review 1.  Inhibiting sexual transmission of HIV-1 infection.

Authors:  Robin J Shattock; John P Moore
Journal:  Nat Rev Microbiol       Date:  2003-10       Impact factor: 60.633

2.  Multiphoton microscopy of cleared mouse brain expressing YFP.

Authors:  Sonia G Parra; Sam S Vesuna; Teresa A Murray; Michael J Levene
Journal:  J Vis Exp       Date:  2012-09-23       Impact factor: 1.355

3.  Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.

Authors:  Sung-Youl Ko; Amarendra Pegu; Rebecca S Rudicell; Zhi-yong Yang; M Gordon Joyce; Xuejun Chen; Keyun Wang; Saran Bao; Thomas D Kraemer; Timo Rath; Ming Zeng; Stephen D Schmidt; John-Paul Todd; Scott R Penzak; Kevin O Saunders; Martha C Nason; Ashley T Haase; Srinivas S Rao; Richard S Blumberg; John R Mascola; Gary J Nabel
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

4.  Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-22       Impact factor: 2.745

5.  Long-term direct visualization of passively transferred fluorophore-conjugated antibodies.

Authors:  Jeffrey R Schneider; Ann M Carias; Arangaserry R Bastian; Gianguido C Cianci; Patrick F Kiser; Ronald S Veazey; Thomas J Hope
Journal:  J Immunol Methods       Date:  2017-08-02       Impact factor: 2.303

6.  Neutralizing antibodies for HIV-1 prevention.

Authors:  Boris Julg; Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

7.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

8.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors:  Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-25       Impact factor: 11.205

9.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

10.  Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Authors:  Peter B Gilbert; Michal Juraska; Allan C deCamp; Shelly Karuna; Srilatha Edupuganti; Nyaradzo Mgodi; Deborah J Donnell; Carter Bentley; Nirupama Sista; Philip Andrew; Abby Isaacs; Yunda Huang; Lily Zhang; Edmund Capparelli; Nidhi Kochar; Jing Wang; Susan H Eshleman; Kenneth H Mayer; Craig A Magaret; John Hural; James G Kublin; Glenda Gray; David C Montefiori; Margarita M Gomez; David N Burns; Julie McElrath; Julie Ledgerwood; Barney S Graham; John R Mascola; Myron Cohen; Lawrence Corey
Journal:  Stat Commun Infect Dis       Date:  2017-06-06
View more
  1 in total

1.  Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs.

Authors:  Chuangqi Wang; Timothy E Schlub; Wen Han Yu; C Sabrina Tan; Karl Stefic; Sara Gianella; Davey M Smith; Douglas A Lauffenburger; Antoine Chaillon; Boris Julg
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.